Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

External quality assessment of BRAF molecular analysis in melanoma.

Journal of clinical pathology - 1 Feb 2014

Deans Zandra C, Wallace Andrew, O'Sullivan Brendan, Purvis Andrew, Camus Suzanne, Fairley Jennifer A, Gonzalez David

Abstract excerpt

The availability of BRAF inhibitors has given metastatic melanoma patients an effective new treatment choice and molecular testing to determine the presence or absence of a BRAF codon 600 mutation is pivotal in the clinical management of these patients. This molecular test must be performed accurately and appropriately to ensure that the patient receives the most suitable treatment in a timely manner....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotyping Techniques
Share to Laboratories

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Quality Assurance, Health Care

Share to Skin Neoplasms

Source

Identifiers

PMID: 24098023
DOI: 10.1136/jclinpath-2013-201848

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

External quality assessment of BRAF molecular analysis in melanoma.PMID 24098023Read ↗

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.Semantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

Implementation of a companion diagnostic in the clinical laboratory: the BRAF example in melanoma.Semantic proximity Read ↗

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

BRAFmutation testing in clinical practiceSemantic proximity Read ↗

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.Semantic proximity Read ↗

Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.Semantic proximity Read ↗

Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.Semantic proximity Read ↗

The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.Semantic proximity Read ↗

BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.Semantic proximity Read ↗

Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.Semantic proximity Read ↗

Results of the UK NEQAS for Molecular Genetics reference sample analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.